AmericanHHM
BD - Earth day 2024

Abbott's ASSERT-IQ™ Insertable Cardiac Monitor Receives CE Mark Broadening Access to Long-Term Heart Rhythm Monitoring

Tuesday, March 26, 2024

Abbott has recently obtained CE Mark approval in Europe for its Assert-IQ™ Insertable Cardiac Monitor (ICM), presenting physicians with an innovative tool for diagnosing and monitoring irregular heart rhythms over extended periods. This approval marks a significant addition to Abbott's range of connected health devices. The Assert-IQ ICM is adept at detecting even subtle irregularities in heartbeats, assisting physicians in determining the most suitable treatment strategies.

Atrial fibrillation, the most common heart arrhythmia, affects over 33.5 million people globally, with its prevalence projected to rise in the coming decades. However, diagnosing arrhythmias, characterized by fleeting irregular heartbeats, poses significant challenges. With the minimally invasive insertion of the Assert-IQ ICM beneath the chest skin, physicians can now continuously monitor the heart and detect arrhythmias, which may manifest as symptoms like fainting and breathlessness. Following implantation, individuals can resume their daily activities while the ICM provides continuous heart monitoring.

Unlike many existing ICMs that offer monitoring for a few years, Assert-IQ introduces two options: one with a battery life of at least three years and another lasting at least six years. The three-year option is suitable for conventional monitoring purposes, such as diagnosing fainting or palpitations, while the six-year option is designed for long-term monitoring in individuals at risk of developing arrhythmias. Both options incorporate advanced algorithms to detect irregular heartbeats and provide clinically relevant data. Assert-IQ ICM's advanced algorithms reduce data overload and enhance device accuracy, ultimately improving physician workflow and efficiency.

As the prevalence of abnormal heart rhythms continues to rise, physicians increasingly rely on ICM technology to diagnose various cardiac conditions. The introduction of Assert-IQ in Europe will expand access to transformative benefits of long-term monitoring, enabling care providers to make quicker and more precise clinical decisions. Assert-IQ represents the next generation of implantable cardiac monitors, offering physicians actionable data and fresh insights into patient care. Its real-time data, advanced algorithms, and diagnostic precision empower physicians to deliver personalized and effective care, providing individuals with abnormal heart rhythms the peace of mind to lead confident lives.

Source: abbott.mediaroom.com

 

 

 

 

Healthcare CEO & Executive Strategy SummitHealthcare CNO SummitHealthcare CMO SummitHealthcare CFO, Financial Strategy & Revenue Cycle SummitThe Healthcare Patient Experience & Engagement Summit 2024Healthcare Innovation & Transformation Summit